Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)18.62
  • Today's Change0.14 / 0.76%
  • Shares traded2.63m
  • 1 Year change-59.96%
  • Beta1.0266
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, cash reserves at RemeGen Co Ltd fell by 1.34bn. Cash Flow from Financing totalled 978.31m or 90.91% of revenues. In addition the company used 1.50bn for operations while cash used for investing totalled 817.65m.
Cash flow per share-2.66
Price/Cash flow per share--
Book value per share5.33
Tangible book value per share5.28
More ▼

Balance sheet in CNYView more

RemeGen Co Ltd has a Debt to Total Capital ratio of 47.37%, a higher figure than the previous year's 14.62%.
Current ratio1.51
Quick ratio1.06
Total debt/total equity0.90
Total debt/total capital0.4737
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.